Most importantly, the expression of CMTM6 in M2 macrophages predicted the response rate to PD-1/PD-L1 inhibitors in CRC patients (5/7, 71.4%) more accurately than dMMR/MSI-H status (2/6, 33%). This evidence concerns the gene CD274 and colorectal carcinoma.